The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

India readies for 600 mln COVID vaccine jabs; to use standard cold storage - top govt expert

Fri, 11th Dec 2020 18:36

* India ready for vaccines needing 2 to 8 degrees Celsius
storage

* AstraZeneca, Bharat Biotech, RDIF's Sputnik V among
frontrunners

* Pfizer, Moderna unlikely to be able to supply India with
volumes
until H2 2021

By Neha Arora and Sanjeev Miglani

NEW DELHI, Dec 11 (Reuters) - India will deploy its vast
election machinery to deliver 600 million doses of COVID-19
vaccines to the most vulnerable people in the next six to eight
months through conventional cold chain systems, the expert
leading the initiative said on Friday.

The government has lined up cold storage facilities with
temperatures between 2 to 8 degrees Celsius (36 to 48°F), said
V.K. Paul, who heads the group of experts on vaccine
administration for COVID-19 that advises India's Prime Minister
Narendra Modi.

Paul said these preparations meet the requirements of what
he said were the four emerging candidates in the race for
India's vaccine.

"The four that I can see, including Serum, Bharat, Zydus,
and Sputnik need normal cold chain. I see no problem for these
vaccines," he told Reuters in an interview.

Serum Institute of India, the world's largest vaccine maker,
is already mass producing and stockpiling AstraZeneca's
Covishield shot, while Indian biotech players Bharat Biotech and
Zydus Cadila are developing their own vaccine candidates.

And last month, Indian pharmaceutical player Hetero inked a
deal with Russia's RDIF to manufacture over 100 million doses of
the Russian Sputnik V COVID-19 vaccine per year in India.

The government expects the first approvals "very soon" from
the independent drug regulator for emergency use, he said.

"I am hoping at the earliest because we are ready."

The government, however, was yet to have formal talks on
pricing and had no firm purchase orders, he said.

"The Indian companies know the government will give a fair
and reasonable price."

SUPPLIES AND STORAGE

At present, Indian regulators are considering three vaccines
for emergency use authorisation, including those from Pfizer Inc
, AstraZeneca and Bharat Biotech.

But, Pfizer's limited stockpiles and its extreme storage
condition requirements at minus 70 degrees Celsius or below,
would likely limit its use in India, which lacks such
infrastructure.

"In a theoretical scenario, where there is no vaccine with
conventional cold chain requirement, minus 70 degrees Celsius
capacities will have to be created, and we will do so," Paul
said.

Paul said the government is also in talks with Moderna
, which also has requirements for ultra-cold storage.

India does not anticipate supplies from either Pfizer or
Moderna until the second half of next year, said Paul.

"We would like to work with them (Moderna) to make that
vaccine available in India, and (ensure) that vaccine is also
manufactured in India - for us and for other countries. This is
the call we have given to Pfizer also and we are in touch with
them as well."

Paul said India may still consider granting Pfizer emergency
use authorisation, despite it not having conducted safety and
immune response trials in India, but said that decision would be
taken by the drugs regulator.

"As of now, it is a norm or standard operating procedure
that any vaccine marketed in India should have human study
results from the Indian subjects," he said.

India has the world's second highest caseload of coronavirus
behind the United States, but its death rate has been far lower.

Still, Paul said the immediate task was to protect lives
and the government had prepared a plan to administer vaccines to
300 million people - or 600 million doses at two jabs each - in
the first part of the programme.

This would be made up of 260 million people above the age of
50, an estimated 10 million below the age of 50 with serious
co-morbidities and 30 million frontline workers, who have borne
the brunt of infections.

"The way it looks as of now, optimistically, it appears
possible to cover the above population of 300 million in six to
eight months' time."

(Reporting by Neha Arora and Sanjeev Miglani; Editing by Euan
Rocha and Raissa Kasolowsky)

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.